Mars Men

Mars-Men (Beijing) Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, focused on the discovery and development of innovative small molecule drugs for oncology and metabolic diseases. The company utilizes a proprietary drug discovery platform to design multi-target inhibitors that aim to provide superior therapeutic outcomes compared to traditional single-target therapies. Its lead candidate, MM-129, is a first-in-class dual inhibitor of PI3K and mTOR currently undergoing Phase 1/2 clinical trials for advanced solid tumors, including hepatocellular carcinoma. Mars-Men's pipeline also includes MM-004, a small molecule GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. The company is led by a team of experienced scientists and is supported by prominent venture capital investors in the healthcare sector.